Ercan Caliskan

Prof. Dr. Ercan Çalışkan graduated from Gülhane Military Medical Academy, Faculty of Military Medicine in 2000 and completed his specialty training in the Department of Skin and Venereal Diseases at the same institution in 2008. In 2011, he was appointed as assistant professor, in 2018 as associate professor and in 2023 as professor.

In his clinical practice, he deals with hidradenitis suppurativa, psoriasis, vitiligo, hair loss, skin cancers and rare diseases (e.g. tuberous sclerosis, lipoid proteinosis). He also performs dermatologic surgery, laser applications and autologous fat and skin-derived regenerative therapies.

His academic studies include surgical approaches, laser applications and animal experiments. He is currently accepting patients and giving trainings at Elos Polyclinic.

Scientific Publications 

Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications. Esme P, Botsali A, Caliskan E. J Wound Care. 2025 

Fat Transplantation: Treating Chronic Fibrosis Caused by Doxorubicin Hydrochloride Extravasation on the Dorsum of the Hand. Çalişkan E, Doğan SN, Tuna A, Botsali A. Dermatol Surg. 2025 Jan 27. 

Clues for Facial Perceived Age: Exercise, Sun Protection, Photoaging, and Anthropometric Properties: An Observational Cross-Sectional Study. Dundar Yolsal O, Esme P, Karahan S, Tasci I, Caliskan E. Dermatol Surg. 2024

 Development of a pig model of spontaneous pressure injury: A randomized self-controlled study.Bakcek Akcelik O, Ayhan H, Ali Aksoy O, Alp Goksel B, Caliskan E, Ceylan A, Ozgenc Cinar OJ Tissue Viability. 2024 

The Comparative Dermal Stimulation Potential of Constant-Volume and Constant-Amount Diluted Calcium Hydroxylapatite Injections Versus the Concentrated Form. Botsali A, Erbil H, Eşme P, Gamsızkan M, Aksoy AO, Caliskan E. Dermatol Surg. 2023

 Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience. Esme P, Akoglu G, Dalkıran CD, Caliskan E. Dermatol Ther. 2022 

An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series. Esme P, Botsali A, Akoglu G, Caliskan E.Skin Appendage Disord. 2022 

Role of exosomes in skin diseases. Kose O, Botsali A, Caliskan E. J Cosmet Dermatol. 2022 Combination of Full-Field and Fractional Erbium: YAG Laser for Nonhealing Wounds. Caliskan E, Botsali A. Lasers Med Sci. 2022;